// App-Quantinova.ai

: Risankizumab in severe asthma: A Phase IIa, placebo-controlled study

Researchers

Presenter

  • Christopher E. Brightling

Principal Investigators

  • Parameswaran Nair

  • Renaud Louis

  • Dave Singh

Medical Centers

  • University of Chester, United Kingdom

  • Firestone Institute for Respiratory Health, Hamilton, ON, Canada,

  • University of Liege, Liege, Belgium.

  • University of Manchester, Manchester, United Kingdom

Locations

  • United Kingdom

  • Canada

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Risankizumab

  • Interleukin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

  • Parallel Group

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved